SCHEDULE: Lightstone Ventures Reports Dilution in ALX Oncology Holdings Stake

Lightstone Ventures and associated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership percentage of ALX Oncology Holdings Inc. due to share dilution.

Summary

• This filing is an amendment (Amendment No. 3) to a previously filed Schedule 13D concerning ALX Oncology Holdings Inc. common stock.
• The amendment reports a dilution in the beneficial ownership percentage of the reporting persons, not due to any acquisition or disposition of securities by them.
• The reporting persons include LSV Associates, LLC, Lightstone Ventures, L.P., Lightstone Ventures (A), L.P., LSV Associates II, LLC, Lightstone Ventures II, L.P., Lightstone Ventures II (A), L.P., Michael A Carusi, Jean George, and Henry A. Plain Jr.
• As of May 1, 2026, the total shares of common stock outstanding for ALX Oncology Holdings Inc. were 134,562,917.
• The reporting persons' beneficial ownership is now below 5% of the issuer's common stock, a threshold they crossed around February 2, 2026, due to dilution from the company issuing additional shares.
• No transactions with respect to the securities of the Issuer have been effected during the past sixty days by any Reporting Person.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reporting persons' decreased ownership percentage resulting from dilution, indicating a potential lack of confidence or strategic shift away from a significant stake.

Negatives

• The reporting persons' beneficial ownership percentage has decreased due to dilution, falling below the 5% threshold.
• This dilution occurred as a result of ALX Oncology Holdings Inc. issuing additional shares of common stock.

Future Outlook

This filing does not contain forward-looking statements or guidance from the company. It solely reports a change in beneficial ownership percentage due to dilution.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes and potential shifts in control or influence within public companies. This particular filing highlights the impact of share issuance and dilution on existing major shareholders, a common occurrence in growth-stage biotechnology companies seeking to fund operations or expansion.

Stakeholder Impact

• Shareholders: The dilution may impact the voting power and proportional ownership of existing shareholders, including the reporting persons. The issuance of new shares could be for strategic growth or operational needs, which may have long-term implications for shareholder value.
• Reporting Persons (Lightstone Ventures entities and individuals): Their beneficial ownership percentage has decreased, potentially affecting their influence and investment thesis. They have not engaged in any transactions to alter their holdings in the past 60 days.

Key Dates

Keywords

ALX Oncology Holdings, Schedule 13D, Beneficial Ownership, Dilution, Lightstone Ventures, LSV Associates, SEC Filing, Common Stock